Merrimack Progresses with MM-111 – Analyst Blog
Merrimack Pharmaceuticals, Inc. ( MACK ) recently advanced its oncology candidate MM 111 to a phase II development. The company …read more
Merrimack Pharmaceuticals, Inc. ( MACK ) recently advanced its oncology candidate MM 111 to a phase II development. The company …read more
Leading apparel retailer, Hanesbrands Inc. ( HBI ) has announced the takeover of the underwear apparel chain, Maidenform Brands Inc. …read more
Diversified media conglomerate Gannett Company, Inc . ( GCI ) is set to offer $500 million senior notes due to …read more
Merck ( MRK ) recently announced that its New Drug Application (NDA) for its anti thrombotic candidate, vorapaxar, was accepted …read more
Associated Banc Corp ( ASBC ) a leading Midwest banking franchise recently announced new share repurchase …read more
MarketAxess Holdings Inc. ( MKTX ) reported second quarter 2013 net earnings of 49cents per share, beating the Zacks Consensus …read more
Astec Industries Inc. ( ASTE ) reported second quarter 2013 earnings of 48 cents per share, up 17% from 41 …read more
By Selena Ing and Adil Yousuf In an industry where major US commercial airlines have experienced near-constant flirtation with …read more
Thermo Fisher Scientific ( TMO ) reported adjusted earnings per share (“EPS”) of $1.32 in the second quarter of fiscal …read more
XOMA Corporation ( XOMA ) recently progressed with its pipeline candidate gevokizumab. XOMA announced that it has completed enrolling patients …read more